Gara Jalqabaatti › Kansa Endometiriyaalii › Massachusetts
Qorannoo klinikaalii Kansa Endometiriyaalii Massachusetts keessatti
Qorannoo 53 Kansa Endometiriyaalii f Massachusetts keessatti hirmaatuu jiru.
Magaalota Massachusetts keessatti
Takkalaa qorannoo (Ingiliffa)
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
- Dana-Farber Cancer Institute, Boston
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Dubartoota · Haaromfame 05-Onk-2026 · NCT07198074Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- Tufts Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
- Baystate Medical Center, Springfield
- fi 1 dabalataa
Namoota walitti qabaa jiraSadarkaa 2
Umuriin hundi · Saalaa hunda · Haaromfame 05-Onk-2026 · NCT05564377Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
- Research Site, Boston
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 hanga 130 · Saalaa hunda · Haaromfame 05-Onk-2026 · NCT05797168A Study of PHST001 in Advanced Solid Tumors
- Dana Farber Cancer Institute, Boston
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 05-Onk-2026 · NCT06840886The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 12 fi ol · Saalaa hunda · Haaromfame 02-Onk-2026 · NCT04585750A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- Dana-Farber Cancer Institute - Oncology Department, Boston
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 02-Onk-2026 · NCT06760819Distance-Based Exercise to Preserve Function and Prevent Disability
- Dana-Farber Cancer Institute, Boston
Namoota walitti qabaa jira
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 02-Onk-2026 · NCT07059884A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
- Dana Farber Cancer Institute, Boston
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 19 fi ol · Saalaa hunda · Haaromfame 01-Onk-2026 · NCT06586957Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
- Massachusetts General Hospital, Boston
- Dana Farber / Harvard Cancer Center, Boston
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Dubartoota · Haaromfame 25-Ful-2026 · NCT03564340Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
- Research Site, Boston
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 25-Ful-2026 · NCT06218914Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
- Massachusetts General Hospital Cancer Center, Boston
- Baystate Medical Center, Springfield
- UMass Memorial Medical Centre, Worcester
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Dubartoota · Haaromfame 24-Ful-2026 · NCT05640999A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute Brookline Avenue, Boston
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Dubartoota · Haaromfame 24-Ful-2026 · NCT04590326A Study of LY4257496 in Participants With Cancer (OMNIRAY)
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 22-Ful-2026 · NCT07114601Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- Dana Farber Cancer Institute, Boston
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 22-Ful-2026 · NCT06128551Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 21-Ful-2026 · NCT05983432A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
- Tufts Medical Center ( Site 6052), Boston
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Dubartoota · Haaromfame 17-Ful-2026 · NCT06952504A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
- Massachusetts General Hospital, Boston
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 17-Ful-2026 · NCT07109726ALPINE: Maintenance Letrozole/Abemaciclib
- Beth Israel Deaconess Medical Center, Boston
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
- fi 1 dabalataa
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 16-Ful-2026 · NCT06366347A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
- Research Site, Boston
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 11-Ful-2026 · NCT05123482Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- Dana Farber Cancer Institute, Boston
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 10-Ful-2026 · NCT06293898Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
- UMass Memorial Medical Ctr, Worcester
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Dubartoota · Haaromfame 09-Ful-2026 · NCT07166094Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer.
- Dana-Farber Cancer Institute, Boston
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Dubartoota · Haaromfame 03-Ful-2026 · NCT07755436A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
- Dana-Farber Cancer Institute, Boston
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 03-Ful-2026 · NCT06515613DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
- Research Site, Boston
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Dubartoota · Haaromfame 03-Ful-2026 · NCT06989112Concurrent Laparoscopic Hysterectomy and Weight Loss Surgery in Obese Patients With Endometrial Carcinoma or Endometrial Intraepithelial Neoplasia
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Namoota walitti qabaa jira
Umuriin 18 fi ol · Dubartoota · Haaromfame 31-Hag-2026 · NCT04839614A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
- Mass General Cancer Center, Boston
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 27-Hag-2026 · NCT07227168A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors
- Dana-Farber Cancer Institute, Boston
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 26-Hag-2026 · NCT07383506Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Dana-Farber Cancer Institute, Boston
Namoota walitti qabaa jiraSadarkaa 1/2
12 Months – 30 Years · Saalaa hunda · Haaromfame 25-Hag-2026 · NCT04851119A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
- Dana Farber Cancer Institute, Boston
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Dubartoota · Haaromfame 21-Hag-2026 · NCT05548296A Phase 1 Study of LNCB74 in Advanced Solid Tumors
- Dana Farber Cancer Institute, Boston
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 21-Hag-2026 · NCT06774963A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
- Massachusetts General Hospital, Boston
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 19-Hag-2026 · NCT04104776A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
- Normunity Investigational Site, Boston
- Normunity Investigational Site, Boston
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 18-Hag-2026 · NCT07182149FOG-001 in Locally Advanced or Metastatic Solid Tumors
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 17-Hag-2026 · NCT05919264A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
- Massachusetts General Hospital Cancer Center, Boston
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 11-Hag-2026 · NCT05592626Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 04-Hag-2026 · NCT05579366First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 07-Ado-2026 · NCT05768139A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
- Mass General Brigham Cancer Institute at Massachusetts General Hospital, Boston
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 29-Wax-2026 · NCT07458347A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 29-Wax-2026 · NCT05377996Integrated Cancer Repository for Cancer Research
- Holyoke Medical Center, Holyoke
Namoota walitti qabaa jiraQorannoo ilaalaaHojjettoota fayyaa simatamoo
Umuriin 19 hanga 110 · Saalaa hunda · Haaromfame 29-Wax-2026 · NCT02012699Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 23-Wax-2026 · NCT06993844Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.